Levodopa/Carbidopa/Entacapone Teva

Levodopa, carbidopa, entacapone, the active ingredients in Levodopa/Carbidopa/Entacapone Teva, are antiparkinson agents presented as an oral tablet for systemic use. They are prescribed to manage Parkinson's disease symptoms by restoring dopamine activity in the brain. These agents work synergistically to increase central dopamine while minimizing peripheral conversion, providing more consistent symptom control for patients across disease stages.

GNH USA supplies Levodopa/Carbidopa/Entacapone Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, delivering the product through regulated supply chains that ensure quality, traceability and compliance with EU standards.

Levodopa/Carbidopa/Entacapone is used in the management of Parkinson's disease, targeting motor fluctuations and overall symptom control. - Parkinson's disease (motor symptoms): improves rigidity, bradykinesia and tremor. - Fluctuating Parkinson's disease (OFF periods): reduces duration and frequency of OFF episodes. - Early-stage Parkinson's disease (initial therapy): helps maintain functional mobility and may delay need for additional dopaminergic agents.

Levodopa/Carbidopa/Entacapone may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset, often occurring after the first doses. - Dizziness: transient light‑headedness, particularly when rising quickly. - Orthostatic hypotension: a noticeable drop in blood pressure upon standing, may cause faintness. - Dyskinesia: involuntary, jerky movements that can affect limbs or facial muscles, usually dose‑dependent.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: rare but life‑threatening reaction characterized by high fever, muscle rigidity, autonomic instability. - Severe depression or suicidal thoughts: may emerge in susceptible individuals and require immediate medical attention. - Cardiac arrhythmias: uncommon irregular heart rhythms that can be serious, especially in patients with pre‑existing heart disease.

When prescribing Levodopa/Carbidopa/Entacapone, clinicians should consider several safety measures. - Initiate therapy under medical supervision: monitor for response and adverse effects. - Adjust dose gradually: avoid rapid increases to reduce dyskinesia risk. - Review concomitant medications: assess for potential interactions that affect dopamine pathways. - Caution in patients with cardiovascular disease: monitor blood pressure and heart rate. - Avoid use in patients with known hypersensitivity to any component. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and light.

Levodopa/Carbidopa/Entacapone can interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: can cause hypertensive crisis when combined. - Antipsychotics with strong dopamine blockade: may diminish therapeutic effect and worsen Parkinsonism.

Moderate Interactions (Monitor Closely): - Selective MAO‑B inhibitors (e.g., selegiline): may increase levodopa levels, requiring dose adjustment. - Antihypertensive agents: additive effect on blood pressure, monitor for hypotension. - Iron or dietary supplements containing high vitamin C: may reduce levodopa absorption, separate administration times.